N-PORT filing recap · October 2020
What did ARK Genomic Revolution ETF buy in October 2020?
Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.
Stock value
$2.78B
Positions
46
Estimated turnover
47.4%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
New positions
EXASExact Sciences Corporation$95.04Mreported value+767.5K sharesTAKTakeda Pharmaceutical Company Limited$30.22Mreported value+1.96M sharesNVSNovartis AG$28.02Mreported value+358.8K sharesBEAMBeam Therapeutics Inc.$17.43Mreported value+510.0K sharesTMOThermo Fisher Scientific Inc.$15.94Mreported value+33.7K sharesREGNRegeneron Pharmaceuticals, Inc.$14.51Mreported value+26.7K sharesRPTXRepare Therapeutics Inc.$7.31Mreported value+270.4K sharesSURFSurface Oncology Inc$4.52Mreported value+539.3K sharesONVOCHFOrganovo Holdings Inc$3.22Mreported value+375.7K sharesAAPLApple Inc.$33.1Kreported value+304 shares